Seth Harrison is founder and managing partner of ATP (Apple Tree Partners), a leading life sciences venture capital firm with $2.65B in committed capital. To date, ATP has launched or invested in over 30 transformative companies focused on delivering cutting-edge therapies for unmet medical needs, out of which 19 so far have gone public or been acquired. Prior to starting ATP in 1999, Seth was a general partner at Oak Investment Partners, and before that a venture partner at Sevin Rosen Funds. From 2002 to 2010, he also served on the board of the International Partnership for Microbicides.

Seth received an A.B. from Princeton University, an M.D. and MBA both from Columbia University, and completed a surgery internship at the Presbyterian Hospital in the City of New York.

Anna Batarina, a partner at ATP, is a leader in international business, capital markets, corporate finance, and strategy. Anna joined ATP in 2016 from Braeburn, an ATP portfolio company, where she served as vice president of Strategic Development. Before Braeburn, she was a member of the strategy team at the Global Fund to Fight AIDS, Tuberculosis and Malaria. Prior to that, Anna was senior vice president and head of Capital Markets and Investor Relations at Uralkali, a leading global agrochemical business, where she led one of the most successful IPOs on the London Stock Exchange.

Anna received an M.A. in Global Affairs (Global Health track) and a graduate certificate in Global Health, Public Health from Yale University. She holds an M.S. in clinical psychology from Lomonosov Moscow State University, a B.S. in finance from Financial University under the Government of the Russian Federation, and a CFA charter.

As CEO of Marengo Therapeutics and a director of the company’s board, Zhen Su brings more than two decades of experiences as a physician-scientist and business executive, with expertise in building and leading both R&D and commercial organizations. Prior to joining Marengo, Zhen served as Senior Vice President and Global Head of Oncology for Merck KGaA, where he led the franchise’s turnaround to achieve double-digit organic growth and an annual revenue above €1B. In this role, he also successfully expanded the oncology portfolio including key alliance partnerships with Pfizer ($2.8B), GSK ($4.2B), and Debiopharm ($1.1B). In his earlier role as Chief Medical Officer of EMD Serono and head of its Oncology Medical division, he played an instrumental role in 8 major regulatory approvals across different indications for Bavencio^®, Tepmetko^®, Erbitux^®, and Mavenclad^®. He also held leadership roles with increasing responsibilities at Sanofi Oncology and GSK. Before his industry career, Zhen served on the faculty of Duke University, where he led early clinical studies focusing on mRNA-based and cell-based immunotherapy, and then the University of Florida, where he was the director of the Cell and Gene Therapy program. He is the author of more than 60 publications in immuno-oncology and targeted oncology.

Zhen earned his M.D. from the Technical University of Dresden, completed his post-doctoral training in tumor immunology at Duke University, and received an MBA from the University of Toronto.

Raj Chopra, Chief Medical Officer of Marengo Therapeutics and a director of the company’s board, is also Head of Oncology and a venture partner at ATP. Raj has deep expertise in cancer cell biology and extensive experience leading R&D efforts in both industry and academia. At The Institute of Cancer Research in London, as director of the Cancer Research UK Cancer Therapeutics Unit, he led one of the largest academic drug discovery groups in the world and focused on targeted protein degradation and complex 3D cell culture models. Raj also worked at Celgene from 2009 to 2016 as corporate vice president of Translational and Early Drug Development, leading an international team of more than 100 scientists. Before joining Celgene, he held leadership positions in AstraZeneca’s Oncology Therapeutics group in the UK and US. Raj started his academic career as the director of Hematological Oncology at Christie Hospital and was group leader at the Paterson Institute of Cancer Research, both located in Manchester, UK. He is a non-executive director of Artios Pharma, established to develop a next-generation DNA damage response target pipeline of cancer therapeutics, and co-founder of Monté Rosa Therapeutics, a biotech focused on targeted protein degradation.

Raj trained in medicine at University College London, where he earned his Ph.D. in medicine, cell and molecular biology. He is a fellow of the Royal College of Physicians of London, the Royal College of Pathologists, and the Royal Society of Biology.

Joseph Yanchik, a venture partner at ATP, has been founding and funding life science companies for more than 20 years. In 2005, Joe founded ATP portfolio company Tokai Pharmaceuticals, focused on biopharmaceutical treatments for prostate cancer, serving as president and CEO from 2005 to 2008 and then as a director through 2017. Concurrently, Joe founded ATP portfolio company Aileron Therapeutics, focused on developing a novel class of stabilized cell-permeating peptides called stapled peptides, for cancer and other diseases. He established a $1.1 billion partnership between Aileron Therapeutics and Roche Pharmaceuticals and led Aileron from inception to public listing, serving as president, CEO, and director from 2006 to 2018. Previously, Joe served as vice president of corporate development at Mendel Biotechnology, an agricultural biotech company, and founded and served as chief financial officer of Poetic Genetics, a gene therapy company. He began his career practicing corporate and securities law at Cahill Gordon & Reindel, where he specialized in public securities offerings, high-yield debt financings, and M&A. He then moved to Venture Law Group in Menlo Park, where he specialized in financing early-stage life science and technology companies.

Joe received a BBA from Loyola College in Maryland and a J.D. from the Villanova University School of Law, where he was managing editor of the Law Review. He is a member of the New York, California, and District of Columbia bars.

Andrew Bayliffe, Chief Scientific Officer of Marengo Therapeutics and a director of the company’s board, has 25 years of leadership experience in the biopharmaceutical industry, with expertise in the discovery and development of both small molecule and antibody therapeutics across a broad range of diseases areas. He held senior roles in antibody discovery and development in the US and UK and worked on early anti-CD3 antibodies, other immune engagers, and TCR-based therapeutics. Most recently, at GlaxoSmithKline (GSK), he served as head of the Fibrosis and Lung Injury Discovery Unit at GSK’s R&D headquarters in Stevenage, UK.

Andrew is a venture partner at ATP (Apple Tree Partners) and an honorary professor at the Wolfson Institute of Experimental Medicine at Queens College in Belfast. He completed his undergraduate and PhD studies in pharmacology, physiology, and molecular biology at Manchester University and Leeds University in the UK.

Andrew Bayliffe, Chief Scientific Officer of Marengo Therapeutics and a director of the company’s board, has 25 years of leadership experience in the biopharmaceutical industry, with expertise in the discovery and development of both small molecule and antibody therapeutics across a broad range of diseases areas. He held senior roles in antibody discovery and development in the US and UK and worked on early anti-CD3 antibodies, other immune engagers, and TCR-based therapeutics. Most recently, at GlaxoSmithKline (GSK), he served as head of the Fibrosis and Lung Injury Discovery Unit at GSK’s R&D headquarters in Stevenage, UK.

Andrew is a venture partner at ATP (Apple Tree Partners) and an honorary professor at the Wolfson Institute of Experimental Medicine at Queens College in Belfast. He completed his undergraduate and PhD studies in pharmacology, physiology, and molecular biology at Manchester University and Leeds University in the UK.

As Chief Medical Officer for Marengo Therapeutics, Kevin brings more than 17 years of biopharma experience in oncology clinical development during which he has worked extensively on T cell directed therapies, particularly checkpoint inhibitors and more recently CAR-T cell therapy for solid tumors and hematologic malignances.

Kevin joins Marengo from 2seventybio, where he was the Head of Clinical Development for the Bluebirdbio spin-off company dedicated to the discovery of next generation CAR T-cell therapies for both hematologic malignancies and solid tumors. At 2seventybio, he was responsible for leading the clinical development organization as it launched Abecma, the first FDA-approved CAR T cell therapy for multiple myeloma, while also initiating first-in-human clinical trials of novel CAR T-cell therapies for B-cell NHL and pediatric AML.

Prior to 2seventybio, Kevin was at EMD Serono where he led the clinical development team for avelumab (anti-PD-L1), which earned global regulatory approvals for Merkel cell carcinoma, urothelial carcinoma, and renal cell carcinoma. Prior to EMD Serono, Kevin started his career in pharma at Bristol-Myers Squibb where he led global clinical development teams for both Ipilimumab (anti-CTLA4) and Nivolumab (anti-PD1).

Kevin completed his undergraduate studies at Princeton University and received his M.D. from the State University of New York – Downstate. He completed his Internal Medicine training and Hematology-Oncology fellowship at Tufts-New England Medical Center in Boston, MA. Kevin also earned a M.S. in Clinical Care Research at the Sackler School of Graduate Biomedical Sciences at Tufts University. Prior to joining the pharmaceutical industry, Kevin was an Assistant Professor of Medicine at Tufts University Medical School and Assistant Director of the Tufts Medical Center Evidence-based Practice Center.

Dr. Coleman has 18 years of experience in the pharmaceutical, biotechnology and complex generics industries with biologics and small molecules across a broad range of disease areas. She most recently served as Vice President and Head of Program Management at Theseus Pharmaceuticals focusing on pan variant KIT inhibitors for GIST and EGFR-mutant NSCLC. Prior to that she served as Executive Director, Head of Program Management at Allena Pharmaceuticals where she managed cross functional program teams through preclinical, Phase 1, Phase 2, and Phase 3 studies for difficult to treat metabolic diseases. From 2006 through 2018, Dr. Coleman held positions of increasing responsibility at Momenta Pharmaceuticals including, Director of Program & Alliance Management, Program leader and CMC team leader for multiple biosimilar programs across numerous indications. She holds a Ph.D. in Organic Chemistry from University College Dublin, Ireland and completed a Postdoctoral Fellowship in Organic Chemistry at the University of Pittsburgh.

As Senior Vice President, Head of Human Resources for Marengo Therapeutics, Alicja is a strategic, impact-driven People & Culture leader who believes that people are the backbone of every organization. With more than 15 years of experience in biotech, pharma, and medical device companies, Alicja translates leadership vision into a talent strategy to make that vision a reality. Previously, she was the Head of the People & Culture at Allena, Theseus Pharmaceuticals, and Agenus. She’s also served in Talent Management leadership roles at Epizyme, Baxalta, and Haemonetics. Alicja shaped her talent development philosophy by spending nearly six years at one of the world’s largest medical device companies, Boston Scientific, where she designed and delivered global talent management initiatives that made Boston Scientific one of the best places to work for years to come.

She proudly serves as a board member with W.E.S.T. Women in Enterprise Science & Technology. She holds a Ph.D. in Sociology from the Polish Academy of Science and is a graduate of the Talent Management Institute, University of North Carolina, Kenan-Flagler Business School.